In a recent interview, Fabio Efficace, Head of the Health Outcomes Research Unit at GIMEMA, discusses findings from the EORTC AML21 trial showing that patient-reported health-related quality of life assessed before treatment provides independent prognostic information on overall survival in patients with acute myeloid leukemia (AML). The results further support the integration of patient-reported outcomes into both clinical research and routine hematology practice.
Read the interview in English: Patient-Reported QoL Offers Prognostic Information in AML
Read the interview in Italian: EHA 2026 – Leucemia mieloide acuta: la voce del paziente aiuta la prognosi